Trials / Completed
CompletedNCT00166387
Hemophilia Inhibitor Genetics Study (HIGS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,137 (actual)
- Sponsor
- Skane University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Several non-genetic and genetic factors that could influence the risk of inhibitor development in hemophilia A have been discussed but not fully explored. The aim of the HIGS is to identify these genetic factors.
Detailed description
The objective of the HIGS is to determine host genetic factors, other than mutations within the factor VIII gene, that are associated with the development of inhibitors in severe hemophilia A and response to antigenic challenge by factor VIII. The study will involve three phases, enrolling family groups composed of brother pairs and their parents (Phase I) and siblings, a family group composed of a person with severe hemophilia and his parents (Phase II), and a group of unrelated people with severe hemophilia for the purpose of confirming associations identified in Phases I and II.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood draw | A single blood draw. |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2005-09-14
- Last updated
- 2014-03-26
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00166387. Inclusion in this directory is not an endorsement.